Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism.

Yao Z, Xing L, Qin C, Schwarz EM, Boyce BF.

J Biol Chem. 2008 Apr 11;283(15):9917-24. doi: 10.1074/jbc.M706415200. Epub 2008 Feb 4.

2.

SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.

Shakespeare WC, Wang Y, Bohacek R, Keenan T, Sundaramoorthi R, Metcalf C 3rd, Dilauro A, Roeloffzen S, Liu S, Saltmarsh J, Paramanathan G, Dalgarno D, Narula S, Pradeepan S, van Schravendijk MR, Keats J, Ram M, Liou S, Adams S, Wardwell S, Bogus J, Iuliucci J, Weigele M, Xing L, Boyce B, Sawyer TK.

Chem Biol Drug Des. 2008 Feb;71(2):97-105. doi: 10.1111/j.1747-0285.2007.00615.x. Epub 2008 Jan 3.

PMID:
18179464
3.

Increased lymphangiogenesis in joints of mice with inflammatory arthritis.

Zhang Q, Lu Y, Proulx ST, Guo R, Yao Z, Schwarz EM, Boyce BF, Xing L.

Arthritis Res Ther. 2007;9(6):R118.

4.

NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.

Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF.

J Biol Chem. 2007 Jun 22;282(25):18245-53. Epub 2007 May 7.

5.

Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing.

Maruyama K, Asai J, Ii M, Thorne T, Losordo DW, D'Amore PA.

Am J Pathol. 2007 Apr;170(4):1178-91.

6.

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems.

Takayanagi H.

Nat Rev Immunol. 2007 Apr;7(4):292-304. Review.

PMID:
17380158
7.

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T.

Clin Cancer Res. 2007 Feb 1;13(3):816-23.

8.

Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes.

Cha HS, Bae EK, Koh JH, Chai JY, Jeon CH, Ahn KS, Kim J, Koh EM.

J Rheumatol. 2007 Jan;34(1):16-9.

PMID:
17216674
9.

The role of the VEGF-C/VEGFR-3 axis in cancer progression.

Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC, Kuo ML.

Br J Cancer. 2007 Feb 26;96(4):541-5. Epub 2006 Dec 12. Review.

10.

The molecular understanding of osteoclast differentiation.

Asagiri M, Takayanagi H.

Bone. 2007 Feb;40(2):251-64. Epub 2006 Nov 13. Review.

PMID:
17098490
11.

SRC inhibitors in metastatic bone disease.

Boyce BF, Xing L, Yao Z, Yamashita T, Shakespeare WC, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6291s-6295s. Review.

12.

Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease.

Boyce BF, Schwarz EM, Xing L.

Curr Opin Rheumatol. 2006 Jul;18(4):427-32. Review.

PMID:
16763465
13.

Biology of vascular endothelial growth factors.

Roy H, Bhardwaj S, Ylä-Herttuala S.

FEBS Lett. 2006 May 22;580(12):2879-87. Epub 2006 Apr 17. Review.

14.

RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.

Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM.

Rheumatology (Oxford). 2006 Sep;45(9):1068-76. Epub 2006 Feb 20.

PMID:
16490750
15.

Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts.

Kaneki H, Guo R, Chen D, Yao Z, Schwarz EM, Zhang YE, Boyce BF, Xing L.

J Biol Chem. 2006 Feb 17;281(7):4326-33. Epub 2005 Dec 22.

16.

Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).

Byrne AM, Bouchier-Hayes DJ, Harmey JH.

J Cell Mol Med. 2005 Oct-Dec;9(4):777-94. Review.

17.

RANKL-RANK signaling in osteoclastogenesis and bone disease.

Wada T, Nakashima T, Hiroshi N, Penninger JM.

Trends Mol Med. 2006 Jan;12(1):17-25. Epub 2005 Dec 13. Review.

PMID:
16356770
18.

Osteoclast precursors, RANKL/RANK, and immunology.

Xing L, Schwarz EM, Boyce BF.

Immunol Rev. 2005 Dec;208:19-29. Review.

PMID:
16313338
19.

RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.

Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA.

Bone. 2006 May;38(5):678-85. Epub 2005 Nov 23.

PMID:
16309985
20.

VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice.

Niida S, Kondo T, Hiratsuka S, Hayashi S, Amizuka N, Noda T, Ikeda K, Shibuya M.

Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14016-21. Epub 2005 Sep 19.

Supplemental Content

Support Center